NASDAQ:CNMD - CONMED Stock Price, Price Target & More

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

CONMED announced a quarterly dividend on Thursday, May 24th. Stockholders of record on Friday, June 15th will be given a dividend of $0.20 per share on Thursday, July 5th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.08%. The ex-dividend date of this dividend is Thursday, June 14th. View CONMED's Dividend History.

CONMED Co. (NASDAQ:CNMD) posted its quarterly earnings results on Wednesday, April, 25th. The medical technology company reported $0.53 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.10. The medical technology company had revenue of $202.10 million for the quarter, compared to analysts' expectations of $196.51 million. CONMED had a net margin of 8.71% and a return on equity of 9.46%. CONMED's revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.38 earnings per share. View CONMED's Earnings History.

CONMED is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for CONMED.

CONMED issued an update on its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share (EPS) guidance of $2.15-$2.20 for the period, compared to the Thomson Reuters consensus estimate of $2.14.

3 Wall Street analysts have issued 12-month price targets for CONMED's shares. Their forecasts range from $46.00 to $73.00. On average, they expect CONMED's share price to reach $59.50 in the next year. This suggests that the stock has a possible downside of 19.5%. View Analyst Ratings for CONMED.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to CONMED include Masimo (MASI), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), NxStage Medical (NXTM), AxoGen, Inc Common Stock (AXGN), Natus Medical (BABY), Viewray (VRAY), Cutera (CUTR), BioLife Solutions (BLFS), Vision Sciences (CGNT), Rockwell Medical (RMTI), Fonar (FONR), Helius Medical Technologies (HSDT), Second Sight Medical Products (EYES) and Zynex Inc. common stock (ZYXI).

Media headlines about CNMD stock have been trending somewhat positive on Tuesday, according to Accern. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CONMED earned a daily sentiment score of 0.07 on Accern's scale. They also gave media stories about the medical technology company an impact score of 44.33 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

CONMED's stock is owned by a number of of institutional and retail investors. Top institutional investors include SCOPIA CAPITAL MANAGEMENT LP (6.60%), Fisher Asset Management LLC (2.09%), Bank of Montreal Can (0.18%) and Campbell & CO Investment Adviser LLC (0.01%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, Luke A Pomilio, Mark E Tryniski, Nathan Folkert and Terence M Berge. View Institutional Ownership Trends for CONMED.

CNMD stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Campbell & CO Investment Adviser LLC. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Jo Ann Golden, Luke A Pomilio, Nathan Folkert and Terence M Berge. View Insider Buying and Selling for CONMED.

CNMD stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, Heather L Cohen and Mark E Tryniski. View Insider Buying and Selling for CONMED.

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CNMD stock can currently be purchased for approximately $73.91.

CONMED has a market capitalization of $2.07 billion and generates $796.39 million in revenue each year. The medical technology company earns $55.48 million in net income (profit) each year or $1.89 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.